ライフサイエンスコーパス: activin receptor

1 possibly through competition for binding to activin receptors.

2 tion and thereby block Nodal from binding to activin receptors.

3 These effects appear to be mediated through activin receptors.

4 ansforming growth factor-beta (TGF-beta) and activin receptors.

5 ansforming growth factor-beta (TGF-beta) and activin receptors.

6 ceptors, and Smad2 and Smad3 by TGF-beta and activin receptors.

7 ACVR2B/Fc, an inhibitor of the Activin Receptor 2B signaling, has been shown to preserv

8 The activin receptor, a transmembrane serine-threonine kinas

9 ion, while expression of a dominant negative activin receptor abolishes ntl and gata5 expression.

10 forms, we have investigated the mechanism of activin receptor activation.

11 RIE cells expressed activin A, the activin receptors ActRI and ActRII, and the follistatin-

12 Type II activin receptors (ActRII and ActRIIB) are single-transm

13 Here, mutations of activin receptors ActRIIA and ActRIIB are shown to disru

14 the activin betaA and betaB subunits and the activin receptors ActRIIA and ActRIIB was demonstrated b

15 high affinity receptor for activin, type II activin receptor (ActRIIA), by administration of the sol

16 The type II activin receptors, ActRIIA and ActRIIB, have been shown

17 tudy we show that disruption of the type IIB activin receptor (ActRIIB) by gene targeting results in

18 low molecular weight complex that stimulated Activin receptor (Acvr) signaling far more potently than

19 generated mice with conditional deletion of activin receptor (ACVR) type 2A, ACVR2B, or both, in ost

20 volvement of the TGFbeta superfamily type II activin receptors, Acvr2a and Acvr2b, in regulating prol

21 s the differential effects of the two type I activin receptors ALK-2 and ALK-4.

22 supports activin cross-linking to the type I activin receptor ALK4.

23 of CRFR2beta replaces the ECD of the type 1B activin receptor (ALK4).

24 nce suggests that ActR-IIB acts as a primary activin receptor and ActR-IB acts as a downstream transd

25 Inhibin also binds type II activin receptors and antagonizes many activin effects.

26 Because Cripto mediates signaling via activin receptors and binds directly to ALK4, we tested

27 compete with activin for binding to type II activin receptors and, thus, prevent activin signaling.

28 g diseases, with a decrease of myostatin and activin receptor, and an increase of the myostatin antag

29 m birth to adulthood, activin betaA subunit, activin receptors, and functional activin antagonists we

30 Inhibin competes with BMPs for type II activin receptors, and this competition is facilitated b

31 which would be, therefore, candidate type II activin receptor antagonists.

32 Thus, the type I and type II activin receptors are involved in overlapping but distin

33 esults provide genetic evidence that type II activin receptors are required for egg cylinder growth,

34 ermore, the effects of constitutively active activin receptors are strictly cell-autonomous.

35 Indeed, we found that both activins and activin receptors are upregulated in duct epithelial cel

36 same two ligands act redundantly through the Activin receptor Babo and its transcriptional mediator S

37 an R7-dependent behavior, we identified the Activin receptor Baboon and the nuclear import adaptor I

38 We find that the Activin receptor Baboon is required in R8 to receive non

39 we have pinpointed the residues required for activin receptor binding and activity, as well as for in

40 diated through a competition for the type II activin receptor but also require the presence of an inh

41 ve shown that Nodal signaling is mediated by activin receptors but also requires EGF-CFC coreceptors,

42 Inhibins also bind type II activin receptors but do not recruit ALK4, providing a c

43 family and drive SMAD2/3 phosphorylation via activin receptors, but activins have not been studied in

44 Nodal and Activin both activate Activin receptors, but only Nodal requires EGF-CFC corec

45 ession of a normally right-sided marker, the activin receptor cAct-RIIa.

46 ressed alone, the type II but not the type I activin receptor can bind activin.

47 or other TGFbeta family members that bind to activin receptors cannot explain development of maxillar

48 ongly with inactive heteromeric TGF-beta and activin receptor complexes and is released upon activati

49 The activin receptor CPE is bound by a Mr 36 x 10(3) protein

50 nsive because they had reduced expression of activin receptors (eg, ALK-4).

51 h that multiple TGF-beta signals converge on Activin receptor/EGF-CFC complexes and suggest a more wi

52 soluble extracellular domain of the type II activin receptor from mouse (ActRII-ECD).

53 onist to the calcium-sensing receptor and an activin receptor fusion protein, which functions as an a

54 recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs.

55 In large part, this function of the activin receptor has been inferred from observations of

56 Activin, Vg-1 and, type II activin receptors have been implicated in regulation of

57 ctivated Smad2 correlated with expression of Activin-Receptor-IB/ALK4, suggesting that although Smad-

58 Analysis of tooth development in activin receptor II and Smad2 mutants shows that a simil

59 We report that RAP-011, an activin receptor IIA (ActRIIA) ligand trap, improved ine

60 type II receptors, such as BMP receptor II, activin receptor IIA, and activin receptor IIB, competed

61 eals the expression of early asymmetry genes activin receptor IIa, sonic hedgehog, Caronte, Lefty-1,

62 (ii) post-natal administration of a soluble activin receptor IIB (ActRIIB-Fc).

63 Our data led us to propose activin receptor IIB as a novel DYNLT1 ligand and sugges

64 In addition, treatment with a soluble activin receptor IIB fusion (sActRIIB-Fc) protein, which

65 LEFTB (formerly LEFTY2) and ACVR2B (encoding activin receptor IIB).

66 s BMP receptor II, activin receptor IIA, and activin receptor IIB, competed with the pd for binding t

67 express myostatin and its putative receptor activin receptor IIB.

68 ignalling are at odds with it behaving as an activin receptor in the early Xenopus embryo.

69 se are the first observations of activin and activin receptor in the normal human breast and in human

70 phenotype obtained using a dominant-negative activin receptor in Xenopus [6], coupled with evidence f

71 s well as constitutively active TGF-beta and activin receptors, indicating that Smad7 transcription w

72 nsitized capsaicin responses and depended on activin receptor kinase activity.

73 tion of RNA encoding a constitutively active activin receptor leads to ectopic expression of gata5 an

74 h a truncated activin/nodal-specific type IB activin receptor leads to efficient neural induction.

75 on with the co-receptor betaglycan, to block activin receptor-ligand binding, complex assembly, and d

76 It includes the activin receptor like kinase 1 gene (ACVRLK1 or ALK1), a

77 d crossveinless 2 (CV2), both induced by the activin receptor like-kinase 1 (ALK1) when stimulated by

78 etween pro- and anti-angiogenic signaling by activin receptor-like kinase (ALK) 1, 5, and TGF-beta ty

79 Several type I receptors exist although activin receptor-like kinase (ALK) 5 mediates the majori

80 I receptor serine/threonine kinase known as activin receptor-like kinase (ALK) 5.

81 , which was impeded by ALK5 knockdown and by activin receptor-like kinase (ALK) receptor inhibitor SB

82 those induced by the receptor serine kinase, activin receptor-like kinase (ALK)-2.

83 BMP-binding TGF-beta superfamily receptors, activin receptor-like kinase (ALK)3/6, and the Smad2/3 p

84 1542) that was identified as an inhibitor of activin receptor-like kinase (ALK)5 (the TGF-beta type I

85 nase domain of the TGF-beta type I receptor [activin receptor-like kinase (ALK)5] and the substrate,

86 Activin receptor-like kinase (ALK)7 is a type I serine/t

87 2 is caused by loss of function mutations in activin receptor-like kinase 1 (ACVRL1 or ALK1).

88 re linked to HHT: endoglin (ENG) in HHT1 and activin receptor-like kinase 1 (ACVRL1; ALK1) in HHT2.

89 Activin receptor-like kinase 1 (Acvrl1; Alk1) is a type

90 We show that vbg encodes activin receptor-like kinase 1 (Acvrl1; also known as Al

91 Activin receptor-like kinase 1 (ALK-1) has homology to t

92 Activin receptor-like kinase 1 (ALK-1), an orphan recept

93 ns were used to determine the involvement of activin receptor-like kinase 1 (ALK1) and ALK5 downstrea

94 dent on the endoglin signaling pathway using activin receptor-like kinase 1 (ALK1) Fc blocking peptid

95 Signaling through high-affinity activin receptor-like kinase 1 (ALK1) in endothelial cel

96 The activin receptor-like kinase 1 (ALK1) is a transforming

97 The activin receptor-like kinase 1 (ALK1) is a type I recept

98 Activin receptor-like kinase 1 (ALK1) is an endothelial

99 Activin receptor-like kinase 1 (ALK1) is an endothelial-

100 e insight into this question by studying the activin receptor-like kinase 1 (ALK1) pathway.

101 Genetic and molecular studies suggest that activin receptor-like kinase 1 (ALK1) plays an important

102 Genetic and molecular studies suggest that activin receptor-like kinase 1 (ALK1), a transforming gr

103 FK506 released FKBP12 from type I receptors activin receptor-like kinase 1 (ALK1), ALK2, and ALK3 an

104 Activin receptor-like kinase 1 (ALK1), an endothelial ce

105 -of-function mutations in the genes encoding activin receptor-like kinase 1 (ALK1), endoglin, Smad4,

106 pro-domain-complexed BMP9 to type I receptor activin receptor-like kinase 1 (ALK1), type II receptors

107 In zebrafish embryos, arterial expression of activin receptor-like kinase 1 (alk1), which encodes a T

108 g was reduced in TbetaRII(+/-) ECs; however, activin receptor-like kinase 1 (ALK1)-mediated Smad1/5 p

109 mutations in one of several genes, including activin receptor-like kinase 1 (ALK1).

110 emorrhagic telangiectasia type 2 (HHT2) with activin receptor-like kinase 1 (ALK1; ACVRL1) mutations

111 e arterial-specific TGFbeta type I receptor, activin receptor-like kinase 1 (ALK1; ACVRL1), causes he

112 Subsequent activation of activin receptor-like kinase 1 enhances expression of No

113 The activin receptor-like kinase 1 gene (ALK-1) is the secon

114 Small interfering RNA knockdown of activin receptor-like kinase 1 inhibited the BMP9-induce

115 to the lack of MGP induces expression of the activin receptor-like kinase 1, a BMP type I receptor, i

116 bone morphogenetic protein receptor type 2, activin receptor-like kinase 1, endoglin, and mothers ag

117 ovenous fate, acting via EphrinB2 and ACVRL1/activin receptor-like kinase 1.

118 IL-1beta reduced the number of activin receptor-like kinase 2 (ALK-2) and ALK-3 recepto

119 dependent upon the type I TGFbeta receptor, activin receptor-like kinase 2 (ALK2), and the downstrea

120 xpression of type I TGFbeta receptors, chick activin receptor-like kinase 2 and 5 increased with a 2.

121 Constitutively active activin receptor-like kinase 2 inhibited Galpha(i2) prom

122 increased with a 2.3-fold higher increase in activin receptor-like kinase 2.

123 f the pVent reporter, which is downstream of activin receptor-like kinase 2.

124 hogenetic protein signaling, most likely via activin receptor-like kinase 3.

125 Activin receptor-like kinase 5 (ALK5) is the major type

126 to the TGF-beta type I receptor (also termed activin receptor-like kinase 5 (ALK5)), in a similar fas

127 growth factor beta receptor I (TGF-betaRI) (activin receptor-like kinase 5 [ALK-5]) and TGF-beta rec

128 he p3TP-lux reporter, which is downstream of activin receptor-like kinase 5 and had no effect on the

129 hese data are consistent with a role for the activin receptor-like kinase 5 in the progression of idi

130 potential of a well-characterized and potent activin receptor-like kinase 5 inhibitor, SB525334 [6-(2

131 at, conversely, the type I TGF-beta receptor activin receptor-like kinase 5 is dispensable for trypsi

132 Aberrant signaling via TGF-beta receptor I/activin receptor-like kinase 5 may be important for both

133 min preferentially induces activation of the activin receptor-like kinase 5 pathway of TGF-beta recep

134 pid acting, and mediated by TGF-beta-induced activin receptor-like kinase 5 signaling in endothelial

135 hic PAH and imply that strategies to inhibit activin receptor-like kinase 5 signaling may have therap

136 oter activity, whereas constitutively active activin receptor-like kinase 5 stimulated Galpha(i2) pro

137 n a small increase in TGF-beta signaling via activin receptor-like kinase 5 to maintain early integri

138 TGFbetaRI kinase/activin receptor-like kinase 5 was inhibited with pharma

139 ylated via JAK1 and acts as a critical ALK5 (activin receptor-like kinase 5) downstream signaling mol

140 ed the TGF-beta type 1 receptor (also termed activin receptor-like kinase 5) in renal epithelial cell

141 ve inhibitor of the type 1 TGF-beta receptor activin receptor-like kinase 5, orally active) to inhibi

142 nt lost-a-fin (laf) is defective in the gene activin receptor-like kinase 8 (alk8), which encodes a n

143 K), transforming growth factor beta receptor/activin receptor-like kinase beta, estrogen receptor, an

144 in zebrafish embryos harboring a mutation in activin receptor-like kinase I (alk1), which encodes a T

145 treatment with Fstl3 or by a pharmacological activin receptor-like kinase inhibitor.

146 treatment of SB-431542, an inhibitor of the activin receptor-like kinase receptors, to enhance myoge

147 anti-activin A-blocking Ab or inhibitors of activin receptor-like kinase receptors.

148 sociate with either nodal or the type I ALK (activin receptor-like kinase) 4 receptor in coimmunoprec

149 s-of-function mutations in the gene encoding activin receptor-like kinase-1 (ACVRL1).

150 Activin receptor-like kinase-1 (ALK1) is an endothelial

151 endogenous BMP-2 ligand and ALK-1 receptor (activin receptor-like kinase-1; known to activate Smads

152 c ossification in transgenic mice expressing activin receptor-like kinase-2 (ALK2) Q207D, a constitut

153 pe II receptor and the type I receptor Alk2 (activin receptor-like kinase-2) decreased.

154 or-beta superfamily receptors and found that activin receptor-like kinase-6 extracellular domain most

155 , saxophone (sax), the ortholog of the human Activin Receptor-Like Kinase1 and -2 (ALK1/ACVRL1 and AL

156 ized the chicken homologues of two mammalian activin receptor-like kinases (ALK), ALK2 and ALK5, and

157 As type I activin receptor-like kinases (ALKs) are necessary for S

158 ta-receptor proteins, including endoglin and activin-receptor-like kinase 1 (ALK1), and BMPR2.

159 pulmonary vascular endothelial expression of activin-receptor-like kinase 1 in normal and diseased pu

160 We identified amino acid changes in activin-receptor-like kinase 1 that were inherited in su

161 Thus, activin receptor-mediated signaling regulates axial patt

162 ment, we predicted in a previous report that activin receptor mRNA expression in embryos might be reg

163 Naturally occurring activin receptor mRNA is maternally inherited and contai

164 r this factor between mRNAs in vivo inhibits activin receptor mRNA polyadenylation.

165 how that not only do endogenous and injected activin receptor mRNAs undergo cytoplasmic polyadenylati

166 C12 and activin receptor mRNAs, both of which contain eCPEs, are

167 ts range is influenced by numbers of type II activin receptors on responding cells.

168 opus Vg1 and GDF1 bind to and signal through Activin receptors only in the presence of EGF-CFC protei

169 describe the role of Baboon (Babo), a type I Activin receptor previously called Atr-I, in Drosophila

170 We find that a constitutively active Activin receptor promotes differentiation throughout the

171 demonstrate that the interaction between the activin receptor R1 and the immunophilin protein FKBP12

172 Transient overexpression of the two types of activin receptor results in ligand-independent receptor

173 et cell and beta-cell proliferation, and the activin receptors RIIA and RIIB are required for the ful

174 ns in the ACVR1 gene, which encodes a type I activin receptor serine/threonine kinase, in 21% of DIPG

175 steoblasts, to determine the contribution of activin receptor signaling in regulating bone mass.

176 Activin receptor signaling, including the transcription

177 Taken together, these results indicate that activin receptor signaling, predominantly through ACVR2A

178 ings suggest that AP-1 mediates FGF, but not activin, receptor signaling during mesoderm induction an

179 ad2 pathways, including a truncated type IIB activin receptor, Smad7 and Ski, induce early neural mar

180 The restricted expression of activin receptor subunits and Smad2 in cells of the adre

181 and-mediated cooperative assembly of BMP and activin receptors that does not rely on receptor-recepto

182 rom the source of activin require functional activin receptors to activate Xbrachyury, a result sugge

183 form heteromeric complexes with the type II activin receptors to mediate activin signal.

184 ad3 may serve as a mediator linking TGF-beta/activin receptors to transcriptional regulation.

185 Conditional deletion of Activin receptor type I (Acvr1) or Smad4 (a downstream t

186 sequence similarity among p50, p53, Tat, and activin receptor type I on these particular lysines was

187 Conversely, activin receptor type II (ActR-II) contributed more to B

188 resonance (BIAcore) we show that BMP-3 binds Activin Receptor type II (ActRII) with Kd approximately

189 Ia (BMPR-Ia)-ECD] and its type II receptor [activin receptor type II (ActRII)-ECD] shows two fundame

190 hree genes likely to be functional (encoding activin receptor type II, a zinc finger, and a putative

191 uired BMP receptor type II (BMPRII), but not activin receptor type IIA (ActRIIA) or ActRIIB, based on

192 and its murine ortholog RAP-011) acts as an activin receptor type IIA ligand trap, increasing hemogl

193 transmembrane domain serine/threonine kinase activin receptor type IIB (ActRIIB) has been proposed to

194 The activin receptor type IIB (ActRIIB) is a transmembrane r

195 ) mice) to investigate effects of a modified activin receptor type IIB (ActRIIB) ligand trap (RAP-536

196 containing the extracellular domain of human activin receptor type IIB (ActRIIB) modified to reduce a

197 inhibited MSTN in adult mice with a soluble activin receptor type IIB and analysed the incorporation

198 We recently reported that an activin receptor type IIB inhibitor produced hypertrophy

199 The ability of the muscles to respond to activin receptor type IIB inhibitor treatment correlated

200 Activin receptor type IIB inhibitor treatment of Mtm1 p.

201 xpressing a dominant-negative MSTN receptor (activin receptor type IIB) in muscle.

202 ing proteins (i.e., nodal, lefty-1, lefty-2, activin receptor type IIB, and Smad2) in L-R axis determ

203 ow and high affinity ligands using a soluble activin receptor type IIB-Fc chimera (ActRIIB.Fc).

204 n in some cell line(s), such as CD87 and the activin receptor type IIB.

205 es have elucidated an important role for the activin-receptor type IIB (ActRIIB) in regulation of mus

206 ptor (ActRII.sTbetaRIII complex) but not for activin receptors (type II + type I) and demonstrate tha

207 e cell line, overexpressing the two types of activin receptor upon induction, in the human erythroleu

208 genetic proteins (BMPs) also utilize type II activin receptors, we hypothesized that BMP signaling mi

209 ressed by oogonia, and the betaB subunit and activin receptors were expressed by both oogonia and som

210 Activin receptors were found widely distributed among ad

211 in the dorsal neural tube interact with the Activin receptors, which signal via a different set of S

212 sruption of signaling by a truncated type II activin receptor, XActRIIB (previously called XAR1), blo

213 the cloning and characterization of a type I activin receptor, XALK4.